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Abstract
Presenilin (PS1 or PS2) is an essential component of the active γ-secretase complex that liberates
the Aβ peptides from amyloid precursor protein (APP). PS1 is regarded as an atypical aspartyl
protease harboring two essential aspartic acids in the context of the sequence D257LV and D385FI,
respectively, rather than the typical DTG...DTG catalytic motif of classical aspartyl proteases. In the
present studies, we introduced the sequence DTG in PS1 at and around the catalytic D257 and
D385 residues to generate three PS1 mutants: D257TG, D385TG, and the double-mutant
D257TG/D385TG. The effects of these changes on the γ-secretase activity in the presence or
absence of γ-secretase inhibitors and modulators were investigated. The results showed that PS1
mutants having D385TG robustly enhanced Aβ42 production compared to the wild type (wt), and
were more sensitive than wt to inhibition by a classical aspartyl protease transition state mimic, and
fenchylamine, a sulfonamide derivative. Unlike wt PS1 and some of its clinical mutants, all three PS1
artificial mutants decreased cleavage of Notch S3-site, suggesting that these artificial mutations may
trigger conformational changes at the substrate docking and catalytic site that cause alteration of
substrate specificity and inhibition pattern. Consistent with this notion, we have found that NSAID
enzymatic inhibitors of COX, known modulators of the γ-secretase activity, cause PS1 mutants
containing D385TG to produce higher levels of both Aβ38 and Aβ42, but to reduce levels of Aβ39,
showing a pattern of Aβ formation different from that observed with wild type PS1 and its clinical
mutants. This study provides an important structural clue for the rational design of drugs to inhibit
processing of APP at the γ-site without interfering with Notch processing.
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Introduction
Strong evidence supports the notion that the aberrant for-
mation and accumulation of β-amyloid peptides (Aβ),
generated from the β-amyloid-precursor protein (APP) by
the action of β- and γ-secretase, is a critical event in the
pathology of familial and sporadic forms of Alzheimer's
Disease (AD) [1-3]. APP is initially cleaved by β-secretase
to generate membrane-bound C-terminal fragments
(CTFs), and a soluble N-terminal ectodomain sAPPβ . Sub-
sequently, those CTFs are cleaved by the γ-secretase within
the putative transmembrane domain to release heteroge-
neous β-amyloid peptides (Aβ) composed of 37 to 43
amino acids; the 40 and 42 amino acids long peptides
referred to as Aβ40 and Aβ42, respectively, are more pre-
dominant and the latter one is the most toxic to neurons
[4]. Moreover, γ-secretase also cleaves APP at the ε-site
(between L49 and V50), which resembles the γ-secretase
S3 cleavage of Notch [5-8], and is located further down-
stream the γ-site with only 2–5 residues inside the cyto-
plasmic membrane [9]. Since the processing of Notch by
the γ-secretase has important physiological implications,
inhibition of its processing needs to be minimized in the
development of γ-secretase inhibitors for AD therapy.
Moreover, a variety of studies have already compiled a
long list of potential γ-secretase cellular substrates that
might further complicate selective inhibition of this
enzyme. These substrates include CD44 [10], LRP [11],
Erb4 [12], Nectin [13], E-cadherin [14]), and two mem-
brane-bound ligands of Notch (Delta and Jagged) [15,16].
Both biochemical and genetic approaches have led to the
discovery that at least four membrane-bound proteins,
presenilin (PS1 or PS2), nicastrin, aph1 and pen2, are
needed to form an active γ-secretase complex [17,18].
Interestingly, only mutations in PS1 and PS2 but not in
the other γ-secretase components are a common cause of
the early onset familial Alzheimer's disease (FAD) [3]. PS1
and PS2 FAD mutants have been shown to increase the
ratio of Aβ42 over total Aβ species [19-22] by affecting γ-
secretase activity through still poorly understood mecha-
nisms. Notwithstanding, recent studies have demon-
strated that a significant increase in absolute levels of Aβ42
was only observed for half of the mutations [23,24], fur-
ther strengthening the notion that the mechanistic effects
of PS1 mutations on the onset of FAD are complex.
Ample evidences suggest that PS1 (or PS2) is not only an
indispensable component of a functional γ-secretase, but
also is its catalytic core. In fact, complete deficiency of PS1
in mice abolishes the processing of both APP to release Aβ
and Notch at the S3 site to release NICD [7,25]. Strikingly,
mutations of the aspartic acid residues to Ala or Glu in
transmembrane segment 6 (TM6) (D257) and TM7
(D385) in PS1 or PS2 (numbering according to PS1)
result in a dramatic reduction of γ-secretase activity [26],
implying the possibility of these two aspartic residues
constitute the active site of the γ-secretase. Aspartyl pro-
tease inhibitors, such as L-685,458 [27,28] and difluoro
ketones [29], were found not only to inhibit γ-secretase
activity but also to locate or extract presenilins from cell
homogenates by approaches including photoaffinity
crosslink and affinity chromatography.
PS1 has a putative topology of nine-transmembrane
domain (TM1 to TM9), and is matured and activated by
cleavage between TM6 and TM7 by a highly regulated
endoproteolytic cellular process that leaves behind tightly
associated N- (NTF) and C-terminal fragments (CTF) [30].
Two conserved aspartic acids, D257 in TM6 and D385 in
TM7, may potentially be positioned to face each other in
an aqueous cavity within the lipid bilayer, and form the
catalytic core [31]. Although mutation of either of these
two conserved aspartic residues PS1 and PS2 impairs γ-
secretase activity [32], they lack the two DTG (or DSG) tri-
plets that form the catalytic pocket found in a typical
aspartyl protease such as β-secretase [33] or HIV protease
[34]. Similar to Presenilins, human signal peptide pepti-
dase (SPP) possesses a pair of aspartic acids [35]. Moreo-
ver, SPP, PS1 and PS2 share highly conserved YD257 and
GXGD385 (PS1 numbering) motifs and constitute a
unique family of aspartyl protease [36].
While mutagenesis of residues surrounding the GXGD
motif is reported [31,37,38], the sequence and structural
contexts following these two essential aspartyl proteases
are not understood. In this study, we artificially intro-
duced either one DTG triplet or both DTG triplets in PS1
and asked whether the DTG triplet could alter γ-secretase
catalytic property due to a structural resemblance to a clas-
sical aspartyl protease. We found that neither the single
D385TG nor the double triplet D257TG/D385TG were
able to convert PS1 into a classic aspartyl protease. How-
ever, D385TG in particular, dramatically elevated Aβ42
production, reinforcing the importance of residues sur-
rounding D385 in the γ-secretase catalytic activity. More
interestingly, PS1-D385TG significantly depressed the
Notch S3-cleavage in releasing NICD, suggesting that the
cleavage of APP at the γ-site and S3-site in Notch are dif-
ferentially regulated. We also found that, unlike wt PS1
and other PS1 familial mutants, PS1-D385TG did not
exhibit a biphasic profile on processing of APP in
response to the inhibition by the γ-secretase inhibitors, L-
685,458 or fenchylamine. We, therefore, propose a possi-
ble model in which PS1-D385TG adopts a conformation,
within the γ-secretase complex, that differs from that of
wt-PS1 and favors the production of Aβ42 but not NICD.
This is the first demonstration that a mutation at
F386I387 to TG causes such a dramatic effect in γ-secretase
activity and inhibition. Because of its unique enzymatic
profiles, PS1-D385TG will be valuable in a comparativeMolecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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structural exploration by approaches including electron
microscope [39] as well as in rational design of drugs that
specifically inhibit Aβ production.
Results
A DTG triplet in PS1 enhances Aβ42 production
In order to explore the potential catalytic effect of the
aspartic acid residues in PS1 TM 6 and 7 domains, we gen-
erated mutant PS1 including those containing either a sin-
gle DTG triplet or both triplets after residue D257 or/and
D385 (see Table 1). The transient transfection experi-
ments were carried out with equal amount of each
mutated PS1 construct and secreted Aβ40 and Aβ42 were
measured by ELISA. Two stable cell lines, named H125.3-
16 and H167-11 cell lines that express human APP carry-
ing Swedish or London mutation respectively, were used
for assessing changes of secreted Aβ40 and Aβ42. The values
of Aβ from the mock (empty pcDNA3 vector) transfected
cells were used for normalization to calculate the %
change in Aβ values obtained after transfection with the
various plasmids shown in column 2. When the H125.3-
16 cells were transfected with wild-type PS1 (wt-PS1), the
ratio of Aβ42 over total Aβ was unchanged (Table 1). As
expected, PS1 mutant carrying the familial mutation (PS1-
M146V) [40,41] cause a preferential production of Aβ42
(Table 1). While mutant PS1 carrying a single DTG triplet
at D257 (PS1-D257TG) behaved similar to wt PS1,
mutant PS1 carrying a single DGT triplet at D385 (PS1-
D385TG) caused a remarkably increased production of
Aβ42 but not Aβ40, and this increase was even more dra-
matic than the above mutants (Table 1). A mutant PS1
containing both the M146V and D385TG mutations was
not any more productive in Aβ42 secretion than either
mutation separately (data not shown), suggesting no syn-
ergistic effect for these two mutations. Transient transfec-
tion of these PS1 mutant constructs into the human IMR-
32 neuroblastoma cells or a mouse neuroblastoma cell
line N2A-APP, which expresses human Swedish APP as
previously described [42,43], also produced similar pat-
terns of Aβ levels (data not shown). We also generated sta-
ble cells expressing both Swedish APP and various PS1
mutants as shown in Table 2. PS1 mutant harboring
D385TG produced about 15-fold higher levels of Aβ42
than control while Aβ40 was only increased by 1.5-fold
than control (Table 2). Similarly, stable cells expressing
PS1-D257TG/D385TG also produced significantly higher
levels of Aβ42 than control cells.
A Western blot of protein extracts from transfected cells
showed that transfected PS1 proteins in various cell lines
are comparable (Figure 1), suggesting that the above shift
of Aβ42 in cells expressing mutant PS1 was not due to the
dramatically altered expression of PS1 variants. Thus, gen-
eration of artificial DTG motif at D385 appears to dramat-
ically favor the production of Aβ42.
The DTG triplet mimics PS1 familial mutation
Previously studies have shown that mutation of either
D257 to A257 or D385 to A385 causes significant reduc-
tion of total Aβ production [26]. To determine whether
the enhanced Aβ42  production seen in PS1-D385TG
mutant was truly due to the introduction of an aspartyl
protease DTG triplet, we then made substitutions to dis-
rupt DTG motif in PS1-D385TG or PS1-D257TG/D385TG
template. Interestingly, disruption of DTG motif in PS1-
D257TA/D385TG, PS1-D257TG/D385TA or PS1-D385TA
template did not cause reversion of the Aβ42/Aβtotal ratio
to the wt PS1 control (Table 3). Similar single mutation in
BACE1 or HIV protease completely abolishes their prote-
olytic activity [44,45]. Thus, the presence of DTG triplet at
D385 does not convert PS1 into a typical aspartyl pro-
tease, but rather creates a mutation that seems to resemble
a PS1 mutation in FAD.
PS1 mutants display differential dose responses to γ-
secretase inhibitors
The effects on the secretion of Aβ, caused by the PS1
mutants harboring the DTG triplet were explored by treat-
ing transfected cells with two well characterized γ-secre-
tase inhibitors: L-685,458, an aspartyl protease transition
Table 1: Transient transfection of various PS1 constructs in HEK-293 cells derived stable cell lines expressing APP carrying Swedish 
mutation (H125.3-16).
Cell Line Transfected PS1 Constructs % change Aβ1–40 % change Aβ1–42 ratio of Aβ42/Aβ
H125.3-16 pcDNA - - 0.065 ± 0.004
" PS1 -5.4 -8.6 0.063 ± 0.004
" PS1-M146V -10.5 33.7 0.095 ± 0.004**
" PS1-D257TG -5.4 -3.6 0.060 ± 0.003
" PS1-D385TG -2.7 233.7 0.193 ± 0.008*
" PS1-D257TG/D385TG -7.1 148.5 0.156 ± 0.001*
The levels of Aβ 40 and 42 were measured 48 hours post transfection.
** p < 0.05 as compared to PS1 wt transfected cells N = 3
* p < 0.01 as compared to PS1 wt transfected cells
Note: Due to the variation of absolute Aβ numbers in different experiments, only the comparative result to the cells transfected with pcDNA was 
used for comparison.Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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state analog [46], and fenchylamine, a sulfonamide deriv-
ative [47]. Production of Aβ40 was initially increased in
APA2 cells (expressing both Swedish APP and wt PS1, ),
APD3 (expressing both Swedish APP and PS1-M146V, ▲ )
and their parental line H125.3-16 (expressing only Swed-
ish APP, ▼ ) upon addition of L-685,458 up to 0.3 µM, but
became reduced with the increased dose of L-685,458
while reaching a complete inhibition at 3 µM (Figure 2A).
The cell line APE12, expressing both Swedish APP and
PS1-D257TG, showed a similar biphasic curve but in a
lower dose range (0.1 µM and 1 µM, respectively; data not
shown). Contrary to the above cases, cell lines expressing
PS1 mutants PS1-D385TG (APB10,) and PS1-D257TG/
D385TG (APC5, +) did not display biphasic curves and
showed inhibition of Aβ40 production at all concentra-
tions of the inhibitor used in the experiments. Interest-
ingly, this non-biphasic curve was also seen in the cell line
H167-11 expressing the London mutation APPV642F
(). This suggests that the conformational changes seen
in APP London mutation are likely compatible with the
D385TG mutation in PS1 during the interaction between
the enzyme and its substrate; both facilitate γ-secretase to
produce Aβ42.
The biphasic effects of L-685,458 on Aβ42 secretion from
the cell lines expressing wt PS1 or familial PS1 mutation
were even more robust than that on Aβ40 secretion (Figure
2B). Again, cell lines expressing either APP London muta-
tion or D385TG triplet displayed no obvious biphasic
effects. It appeared that L-685,458 has less inhibitory
potency on Aβ42 production than on Aβ40 production as it
required a higher dose to inhibit Aβ42 than Aβ40 in cells
expressing PS1 carrying D385TG triplet. Cell toxicity was
not obvious during the treatments with this drug up to 30
µM for any of the cell lines tested (data not shown),
Table 2: Examination of Aβ values from conditioned media of HEK-293 derived stable cell lines expressing both Swedish APP and each 
of PS1 genes.
Cell Line Transfected PS1 Constructs Aβ1–40 (pg/ml) Aβ1–42 (pg/ml) Ratio of Aβ42/Aβ
H125.3-16 ---- 3152 ± 47 (n = 6) 337 ± 36 (n = 6) 0.097 ± 0.010
" PS1 8379 ± 170 (n = 3) 1123 ± 20 (n = 6) 0.118 ± 0.002
" PS1-M146V 9507 ± 129 (n = 3) 2627 ± 52 (n = 3) 0.217 ± 0.004**
" PS1-D257TG 9716 ± 192 (n = 3) 1099 ± 35 (n = 6) 0.102 ± 0.003*
" PS1-D385TG 7783 ± 225 (n = 3) 16647 ± 799 (n = 3) 0.681 ± 0.033**
" PS1-D257TG/D385TG 5390 ± 218 (n = 3) 6941 ± 97 (n = 3) 0.563 ± 0.008**
n = 3 to 6 wells in one experiment. Aβ represents total Aβ.
*, p < 0.001, **, p < 0.0001 as compared to PS1 wt transfected cells
Expression of PS1 variants in each stable cell line Figure 1
Expression of PS1 variants in each stable cell line. Western blot of equal amount of cell extracts from the stable cell 
lines expressing the indicated PS1 variants. The blot was probed with mixed antisera recognizing both N- and C-terminus of 
PS1.Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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excluding the possibility that the Aβ reduction seen in the
above experiments was due to drug toxicity.
A biphasic production of Aβ40 was also seen in H125.3-16
(+), H143.3 (Ќ), and APA2 () cell lines treated with the
less potent γ-secretase inhibitor fenchylamine sulfona-
mide: it took 12 µM to reach the peak of enzymatic activ-
ity and 30 µM to achieve complete inhibition (Figure 3A).
Cells expressing PS1-D257TG (APE12) were also more
sensitive to the drug treatment with 3 µM for the full stim-
ulation (data not shown). Again, cells expressing PS1
D385TG mutants (APB10, ❍ ) showed highest sensitivity
to the treatment with non-biphasic responses (Figure 3A).
Similarly, there appeared no biphasic Aβ40 production in
cells expressing APP London mutation when treated with
fenchylamine sulfonamide.
For the production of Aβ42, fenchylamine sulfonamide
produced a large stimulus response on cells expressing
endogenous PS1 or transfected wt PS1, but had a weak
stimulating effect or no inhibition on the other cell lines
(Figure 3B). The stimulating effect was probably due to
the low potency of this drug on the inhibition of γ-secre-
tase activity in producing Aβ42, and the biphasic effect
reflects a low inhibitory profile.
NSAIDs display differential effects on PS1 mutants
The nonselective COX inhibitors NSAIDs Ibuprofen,
Indomethacin and Sulindac sulfide (an active metabolite
of the pro-drug Sulindac) have been shown to reduce Aβ42
levels through increasing Aβ38 production [48], suggesting
that NSAIDs can modulate γ-secretase activity. We found
that all of the above compounds lowered Aβ42 secretion in
a dose dependent manner in APB10 cell line expressing
both Swedish APP and PS1-D385TG or APD cell line
expressing both Swedish APP and the clinical mutation of
PS1 M146V (Table 4). Sulindac sulfide was the most
potent, followed by Indomethacin and Ibuprofen, show-
ing 50% inhibition at about 30–50 µM for Sulindac
Sulfide, 50–150 µM for Indomethacin and 300 µM for
Ibuprofen. The nonselective COX inhibitors NSAIDs Aspi-
rin (Acetylsalicylic acid) and Naproxen did not have any
inhibitory effect (data not shown). The COX-2 NSAID
inhibitor Meloxicam showed about 50% inhibition at
300 µM for both Aβ40 and Aβ42 which was similar to Ibu-
profen for Aβ42, while Ibuprofen showed no effect on Aβ40
production.
To examine the Aβ species under the treated conditions,
media from the three tested cell lines expressing PS1, PS1-
D385TG and PS1-M146V were collected, and Aβ peptides
were immunoprecipitated with monoclonal antibody
4G8. Sulindac Sulfide at a concentration of 100 µM was
chosen for treating the cell lines for its potent inhibitory
effects seen in the above experiments. The immunoprecip-
Table 3: Transient transfection of various PS1 constructs in 
HEK-293 cells derived stable cell lines expressing APP carrying 
Swedish mutation (H125-16).
Cell Line Transfected PS1 Constructs Ratio of Aβ42/Aβ
H125.3-16 PS1 0.082 ± 0.022
" PS1-D385TG 0.261 ± 0.029**
"P S 1 - D 3 8 5 T A 0.212 ± 0.007**
"P S 1 - D 2 5 7 T A /D385TG 0.186 ± 0.010**
" PS1- D257TG/D385TA 0.171 ± 0.005**
Aβ40 and Aβ42 levels were measured 48 hrs post-transfection.
** p < 0.01 (versus PS1 wt) N = 3
Changed residue in the DTG motif was shown in underlined.
The relative Aβ level secreted in the various stable cell lines  treated with L-685,458 Figure 2
The relative Aβ level secreted in the various stable 
cell lines treated with L-685,458. Aβ40 (A) and Aβ42 (B) 
were measured by ELISA 24 hours post treatment with the 
γ-secretase inhibitor L-685,458 (n = 2). The untreated sam-
ples were used for normalization. H125.3-16 (APP-Sw, Ќ), 
APA2 (APP-Sw + PS1, ), APB10 (APP-Sw + PS1-D385TG, 
❍ ), APC5 (APP-Sw + PS1-D257TG/D385TG, +), APD3 
(APP-Sw + PS1-M146V, ▲ ) and H167-11 (APPV642F, ).Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
Page 6 of 12
(page number not for citation purposes)
itates were examined on bicine-urea gels to have better
resolution of various Aβ species [48]. As shown in Figure
4, Aβ40 was a predominant species in this wt-PS1 express-
ing H125.3-16 cell line (Figure 4, lane 1). Aβ42 accounted
for only 13% of total Aβ species that is defined as the sum
of the Aβ 38, 39, 40, and 42 bands (as determined by opti-
cal density measurements). As expected, the H125.3-16
cells treated with Sulindac Sulfide produced no measura-
ble Aβ42 while Aβ38 was increased from 15% to 33% of
total Aβ species (Figure 4 lanes 2). Prior to any treatment,
substantially more Aβ42 was produced in PS1-D385TG
expressing cells (Figure 4 lanes 3) than in cells expressing
either endogenous levels of wt PS1 (lanes 1) or PS1-
M146V (lanes 5), and this was in consistent with the
ELISA results. The Western blot results also indicated that
PS1-D385TG elevated Aβ38 and Aβ39 production, and the
increased Aβ42 species accounted for only 25% of the total
Aβ in PS1-D385TG-expressing cells instead of 33% in
PS1-M146V-expressing APC5 cells. After Sulindac Sulfide
treatment, Aβ42 formation was completely shifted to Aβ38
in both H125.3-16 and APC5 cell lines (Figure 4, lanes 2
and 6). However, Aβ42  production was only partially
reduced in PS1-D385TG-expressing cells under the same
treatment conditions (Figure 4, lane 4). As noted, while
the levels of Aβ38 were increased from 25% of total Aβ spe-
cies to 33% in the PS1-D385TG expressing cells treated
with 100 µM Sulindac Sulfide, it was the Aβ39 which had
a more significant decline from 20% to undetectable in
respect to the total Aβ species (Figure 4, lane 4). Appar-
ently, NSAID has differential affects on the selective cleav-
age of APP-CTFs by the γ-secretase activity when PS1 is
mutated.
Differential effects on Notch S3-cleavage in PS1 mutants
Notch receptors undergo three distinct proteolytic cleav-
ages during maturation and activation, and the third
cleavage of Notch (S3 site) occurs within the plasma
membrane by the PS1-containing γ-secretase and results
in the release and translocation of the intracellular
domain into the nucleus to execute Notch signaling [49].
To determine whether the PS1 mutations carrying the
DTG triplet would affect Notch processing, we developed
a protocol based on the translocation of the Notch intrac-
ellular domain (NICD) to the nucleus after S3 cleavage
[50]. For each of the 5 cell lines examined, cleavage of
Notch by the γ-secretase activity was determined based on
luciferase activity that measures binding of NICD to the
reporter. Figure 5 summarized results from three inde-
pendent experiments. While the clinical mutation PS1-
M146V showed similar processing activity at the S3 site to
the wild type PS1, a significant reduction of S3 cleavage
was found in cells expressing PS1 mutants containing
DTG motif at D385 (Figure 5). Specifically, the Notch
cleavage activities of PS1-D385TG, PS1-DTG/DTG, PS1-
D257TG and PS1-M146V have decreased by about 62%,
46%, 22% and 7%, respectively, compared to PS1wt activ-
ity (Figure 5). Obviously, the mutations in PS1 containing
a DTG motif caused a significant change in the conforma-
tion in the γ-secretase complex that is not favoring the
cleavage of the Notch substrate.
Discussion
The triplets D257LV and D385FI, found in human PS1
TM 6 and 7, respectively, are conserved across species, and
mutations of D257 and/or D385 to Ala result in essen-
tially a complete loss of activity [26], suggesting that PS1
may function like an aspartyl protease. In addition, PS1
shares the YD257 and GxGD385 motifs with a unique
family of aspartyl proteases referred to as signal peptidases
The relative Aβ level secreted in the various stable cell lines  treated with fenchylamine sulfonamide Figure 3
The relative Aβ level secreted in the various stable 
cell lines treated with fenchylamine sulfonamide. 
Aβ40 (A) and Aβ42 (B) were measured by ELISA 24 hours 
post treatment with the γ-secretase inhibitor fenchylamine 
sulfonamide (n = 2). The untreated samples were used for 
normalization. The symbol for each cell lines is the same as in 
Figure 2.Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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(SPP) [35]. While the role of the amino acids comprising
the YD257 and GxGD385 motifs have been studied, the
couple of amino acids following D385, in particular F386,
have not been tested. Since the two conserved catalytic
aspartic acids D257 and D385 are not in the context of the
two DTG (or DSG) catalytic triplets of a classical aspartyl
protease [51], we artificially replaced L258V259 and/or
F386I387 with TG in PS1 to generate two PS1 mutants
D257TG and D385TG, and the double-mutant D257TG/
D385TG; we then investigated the effect of these muta-
tions on γ-secretase catalytic activity in the presence or
absence of γ-secretase inhibitors. Our data shows that
expression of the PS1-D257TG in a stable cell line Swed-
ish APP did not significantly alter the production of Aβ40
or Aβ42 (data not shown). However, when the same exper-
iment was carried out with PS1-D385TG or PS1-D257TG/
D385TG, levels of Aβ42 were increased at least 2.5 fold
compared to that with wt PS1 whereas Aβ40 remained
largely unchanged. It appears that the mutation of
F386I387 to T386G387 greatly favors the formation of
Aβ42.
Table 4: Effects of selected NSAID compounds on Aβ production from indicated cell lines.
Cell Lines NSAID Dose (µM) Aβ40 (% of vehicle) Aβ42 (% of vehicle)
APC5 cell line (S) Ibuprofen 0 100 100
33 101 ± 8 96 ± 17
100 96 ± 15 79 ± 21
300 70 ± 13 * 62 ± 9 *
Indomethacin 0 100 100
33 101 ± 11 79 ± 21
100 93 ± 14 53 ± 12 *
300 68 ± 11 11 ± 4 *
Sulindac Sulfide 0 100 100
11 103 88
33 96 ± 5 64 ± 2 *
100 57 ± 2 * 3 ± 1 *
APD3 cell line (S) Ibuprofen 0 100 100
33 135 ± 19 88
100 119 ± 34 64 ± 2 *
300 103 ± 36 31 ± 11 *
Indomethacin 0 100 100
33 95 ± 22 52 ± 15 *
100 92 ± 12 * 13 ± 11 *
300 72 ± 16 * 0 *
Sulindac Sulfide 0 100 100
11 111 76
33 128 ± 18 56 ± 4 *
100 64 ± 10 * 0 *
• * p < 0.05
• Note: at 11 µM Sulindac sulfide only one experiment was run which was the repeat experiment; due to the fact that this drug showed more 
potency than the others at lower doses that dose was added and the 300 µM dose was omitted since it exhibited toxicity on the cells
Each dose was run in triplicate.
Western blot of immunoprecipitated Aβ species Figure 4
Western blot of immunoprecipitated Aβ species. 
Conditioned media collected from the cell lines that express 
wt PS1, PS1-D385TG or PS1-M146V and were treated with 
either DMSO or 100 µM Sulindac Sulfide. Equal amount of 
the media was immunoprecipitated with monoclonal anti-
body 4G8 and the extensively washed immunoprecipitates 
were resolved on a Tricine-Urea gel. The blot was reacted 
with antibody 6E10 for detection.Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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Equally interestingly, the F386I387 to T386G387 muta-
tion results in a significant reduction in processing of
Notch at the S3 site APP ε-site (ITL49↓V50ML) (Chen,
2001; Weidemann, 2002). Indeed, our preliminary exper-
iments based on a reporter-depending assay suggested
that both PS1-D385TG and PS1-D257TG/D385T also
reduced processing at the APP ε-site (data not shown); yet,
this latter observation needs to be fully validated. It
appears that the mutation of F386I387 to T386G387
greatly favors the formation of Aβ42 and decreases the
cleavage at both APP ε- and Notch S3-site.
We have shown that this enhanced production of Aβ42 in
PS1-D385TG is not due to the conversion of PS1 into a
classic aspartyl protease because the mutated triplet
D385TA still increases production of Aβ42 to a certain
extent (Table 3). In light of these and other findings (Tolia
et al, 2006;Yamasaki et al., 2006), it appears that mutating
I387 may have a minor effect on the γ-secretase activity.
Instead, the effect is driven by the F386 to T386 mutation.
The presenilin and signal peptidase consensus motif
GxGD has been studied with regard to its role in the con-
text of the γ-secretase activity. Interestingly, the clinical
PS1 G384A mutant increased Aβ42 production by a factor
of 6, but had no significant effect on Notch processing
[52]. On the contrary, phenylalanine at position × of the
GxGD385 motif in PS1 is suggested to be responsible for
altering Notch processing [38]. Together with our findings
that the mutation of F386 to T carries most of the respon-
sibility for the observed change in substrate preference, we
support the notion that the sequences surrounding the
D385 may be critical in determining γ-secretase substrate
recognition and docking, enzyme specificity and substrate
cleavage rate. Although D257 is also implicated as a criti-
cal residue in cleaving APP at the γ-secretase site, PS1-
D257TG has less effect on the elevation of Aβ 42 and
reducing Notch cleavage in our experiment. This weak
effect is likely due to the presence of wild type PS1 in our
cell lines as suggested by others [53].
Consistently, PS1-D257TG and PS1-D385TG mutants
were also affected differently by γ-secretase inhibitors in
our studies when compared to the wild type or clinical
mutants. Both wild type and most PS1 variants showed
biphasic curves, stimulation at low inhibitor concentra-
tion followed by inhibition at higher concentration, to the
PS1 carrying D385TG triplet suppresses NICD production Figure 5
PS1 carrying D385TG triplet suppresses NICD production. Each indicated stable cell was transfected with the Notch 
∆E-GVP, pFR-Luc and pRL-CMV. In Notch ∆E-GVP, the Notch ∆E protein was fused to VP16 transactivating protein domains 
(GVP). After the cleavage of the N ∆EGVP by the γ-secretase, the Notch ∆E-GVP intracellular domain will translocate to the 
nucleus and binds to the GAL4 DNA binding domain located in the upstream of the reporter pFR-Luc to activates transcrip-
tion. The results are the average of the three experiments.Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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γ-secretase inhibitor L-685,458 while the PS1-D385TG
mutants showed normal dose-dependent inhibitory
curves within the test range. This stimulation/inhibition
behavior has been reported for a variety of apparently
unrelated inhibitors, including aspartyl protease transi-
tion state inhibitors, both in cells and in cell-free assay of
γ-secretase activity [54-57]. Indeed, increases of Aβ42 up to
8-fold were observed at the peak elevation, and Aβ 42 con-
stituted as much as 50% of the total secreted Aβ [54].
Among the various mechanisms suggested to justify this
phenomenon there is one involving an allosteric modula-
tion of the γ-secretase complex by a process similar to that
responsible for the increase of Aβ 42 production by FAD
mutations in presenilins, possibly related to structural
changes; and another one related to inhibitor binding to
either PS allosteric sites or the cell membrane which
would cause structural changes in the preseniln structure
to favor Aβ 42 production prior to reaching inhibitory
concentrations. No matter which stimulation/inhibition
mechanism is operative, our PS1-D385TG mutant distin-
guishes itself from wild type and other mutants in that
this mutation has changed the enzyme structure suffi-
ciently to have a significant effect in its ability to recognize
and cleave substrates and be inhibited. On the other
hand, the mutation leading to PS1-D257TG has much less
influence on inhibition than PS1-D385TG; yet it may be
able to induce some minor structural changes since it is
inhibited by lower concentrations of inhibitor than the
wild type enzyme (data not shown).
It has been reported that the γ-secretase is composed of
one of each of the following proteins: presenilin, nicas-
trin, aph1 and pen2 [58]. If this stoichiometry is correct,
our results would favor a model which comprises a γ-
secretase catalytic site with D257 and D385 as catalytic
residues and F386 involved in substrate docking with
other residues possibly from the GLGD385 motif. How-
ever, a different stoichiometry involving two molecules of
presenilin per γ-secretase complex has been reported
(Clarke et al. 2006; Schroeter et al, 2003). If the latter sto-
ichiometry is true, an additional model could also be pos-
sible where two C-terminal fragments or two N-terminal
fragments form a homodimer with two D385s or two
D257s, respectively, as catalytic residues. Based on the
larger effect exhibited by mutations around D385 than
those produced by mutations around D257, we suggest
that the mutations F386I387 to T386G387, particularly
F386 to T, following the catalytic residue D385 in TMD7
of PS, are involved in APP/Notch substrate selection and
in substrate docking at the active site of γ-secretase.
Earlier work [48] showed that, in cultured cells, certain
NSAIDs were able to decrease Aβ42 secretion with con-
comitant increase in the Aβ38, suggesting a correlation
between Aβ42  decrease/increase and Aβ38  increase/
decrease. Recent work [59] has examined 10 clinical
mutants of PS1 and shown that Sulindac Sulfide could
increase the formation of Aβ38 without affecting Aβ42. Yet,
these investigators observed that wt PS1 and even more
PS1 M146L had a significant decrease of Aβ42 and increase
of Aβ38 upon treatment with 50 µM sulindac sulfide.
These latter observations are consistent, at least qualita-
tively, with those of the present study. Specifically, we
show (Figure 4) that Sulindac Sulfide treated wt PS1, PS1
M146V, and PS1-D385TG, result in less Aβ42 production
with a significant Aβ38 increase. Yet, while the two former
proteins have a complete competence to produce Aβ42,
the latter one has totally lost its ability to form Aβ39, and
only partially that of making Aβ42 and Aβ40. The nature of
these differences might be related to induction of confor-
mational changes on these PS1 molecules by Sulindac
Sulfide treatment [60] and are apparently different than
those induced on most of the clinical mutants explored in
the previous studies as reflected by the different effects on
Aβ production [59].
In summary, we have, for the first time, demonstrated that
a mutation at F386I387 to TG in PS1 causes a dramatic
effect on γ-secretase activity with respect to higher produc-
tions of Aβ42 compared to wt PS1, and differential proteo-
lytic cleavages of its two studied substrates by increasing
cleavage of APP after residue 42 (yielding Aβ42) while
decreasing the cleavage at the Notch S3-site. The knowl-
edge gained from this study provides useful information
in rational design and in the development of a protocol to
screen compounds that only block the γ-secretase activity
toward APP to release Aβ but not the other substrates.
PS1-D385TG can be used as a tool for comparative studies
of structure and conformation in the γ-secretase complex.
Materials and methods
Development of APP/PS1 Stable Cell Lines
HEK-293 cells were initially transfected with sixteen µg of
DNA (pcDNA3.1/Hygro- vector inserted with either APP
Swedish or London mutant. Two selected stable cell lines
expressing Swedish APP were designated to be H143.3-23
and H125.3-16 while H167-11 for the cell line APP Lon-
don mutant. A similar procedure was followed for the
establishment of 125.3-16 cells that express PS1, PS1-
D385TG, PS1-D257TG/D385TG, PS1-M146V, or PS1-
D257TG cDNA inserts. The table below shows the
nomenclature for the APP/PS1 stable cell lines and the
clone used for follow-up studies. Three to ten clones were
picked for each cell line and examined for the levels of
Aβ40 and Aβ42 in conditioned media. The average ratio of
Aβ42/total-Aβ for ten wt PS1-clones was 0.139 ± 0.22;
0.644 ± 0.089 for nine PS1-D385TG clones; 0.564 ± 0.133
for five PS1-D257TG/D385TG clones, 0.240 ± 0.033 for
three PS1-M146V clones, and 0.087 ± 0.044 for ten PS1-Molecular Neurodegeneration 2008, 3:6 http://www.molecularneurodegeneration.com/content/3/1/6
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D257TG clones. One clone for each PS1 DNA construct
was selected from the set of clones for follow-up.
H125.3-16 APP-Sw
APA clone #2 APP-Sw + PS1 wt
APB clone #10 APP-Sw + PS1-D385TG
APC clone #5 APP-Sw + PS1-D257TG/D385TG
APD clone #3 APP-Sw + PS1-M146V
APE clone #12 APP-Sw + PS1-D257TG
Notch Assays
Notch undergoes cleavage by the γ-secretase to release
NICD that will translocate into nucleus to result in expres-
sion of target gene. To examine this cleavage, cell lines
were seeded in 6 well dishes at 6 × 105 cells per ml (2 ml/
well) and each well was transfected with 6.25 ng Notch
∆E-GVP [61], 1.55 µg pFR-Luc (UAS-firefly luciferase,
Stratagene), and 62.5 ng pRL-CMV (renilla luciferase,
Promega) for the luciferase assay or 2 µg Notch1∆E for the
Notch the next day. After incubation for 3 hrs, transfection
media was replaced with growth media and cells were
allowed to grow for an additional 48 hrs. Luciferase assay
were performed according to the protocols from manufac-
turer (Dual-Luciferase Reporter Assay System, Promega).
Briefly, each well was washed twice with PBS and har-
vested with 500 µl PLB buffer Lysates were transferred to
eppendorf tubes and allowed to freeze at -80° for up to
one week before being assayed. Lysates (2 or 20 µl) was
transferred to each well of a 96 well plate and luciferase
activity was measured using the Promega Dual-Luciferase
reagents and a Lumiskan Ascent luminometer (Thermo-
Labsystems).
ELISA Assay
The analysis of Aβ levels from conditioned media under
specified conditions was performed as described previ-
ously [62]. Statistical analysis of the Aβ40 and Aβ42 levels
was performed using the Student's t-test.
Immunoprecipitation and Western blot Assay
Cells were first grown in DMEM media for 24 hours in 6
well dishes to near confluence and then treated with drugs
such as 100 µM of sulindac sulfide in 1% DMSO. After
incubation for 24 hrs, one ml of conditioned media was
used for immunoprecipitation with monoclonal antibody
4G8 under standard overnight immunoprecipitation con-
ditions as described previously [63]. The extensively
washed immunoprecipitates were resolved on a Tricine-
Urea gel. For Western with cell lysates, cell extracts were
prepared in TENT buffer (50 mM Tris pH 8.0, 150 mM
NaCl, 2 mM EDTA and 1% Triton X-100) with protease
inhibitor cocktails. Equal amount of protein extracts were
resolved on a 4–12% NuPage Bis Tris gel from Invitrogen
(Carlsbad, CA). Monoclonal antibody 6E10 was used to
detect Aβ species.
Drug Treatment
Cells were plated at 50 to 100 thousand per well. After 48
hours, when cells were confluent, medium was replaced
by cell medium containing the drug at each dilution. Each
drug dilution was run in triplicate wells. After 24 hours
incubation, half the volume of the conditioned cell
medium was collected for measuring Aβ40 and Aβ42 by
ELISA, while the remaining was saved for replication. The
plate with the remaining cells was used for the MTS reduc-
tion assay to assess drug toxicity to the cells. All drugs were
dissolved in DMSO at a concentration 1000 fold higher
than the final drug concentration in the cell media for a
final concentration of DMSO of 0.1%. The drugs used
were Fenchylamine, L-685,458 (from Bachem), Sulindac
sulfide and sulfone (a second metabolite of Sulindac) (all
from Biomol Research Labs Inc.), Acetylsalicylic acid
(from ICN), (S)-Naproxen (from Cayman Chemical Co),
Meloxicam (from Calbiochem). The experiment with the
selective γ-secretase inhibitors was replicated. The com-
parison was made between Aβ40 and Aβ42 levels after drug
treatment versus mock treated control. Cellular toxicity in
treated cells was evaluated according to the procedures as
previously described [64].
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